CNTX News and Press, Context Therapeutics Inc. From 08/06/25

CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeut...

Sera Prognostics Inc. (SERA) is expected to report $-0.21 for Q2 2025 D/B/A Compass Diversified Holdings Shares of Beneficial Interest (CODI) is expected to report $0.51 for Q2 2025 Context Therapeutics Inc. (CNTX) is expected to report $-0.06 for Q2 2025 Genco Shipping & Trading ...

Context Therapeutics Inc. (CNTX) is expected to report $-0.06 for Q2 2025

2025-07-07 11:00:00 ET The continued rally in the S&P 500 in June again validated the buy-the-dip strategy. Are there any compelling investment ideas out there that may have flown under your radar?... Read the full article on Seeking Alpha For further details see: ...

2025-06-10 07:10:43 ET Context Therapeutics ( CNTX ) is a clinical stage biotechnology company developing treatments for solid cancerous tumors using novel Bispecific T-cell engaging (BS-TCE or B-TCE or BiTE) technologies. Considerable work has been undertaken in the BS-TCE aren...

Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clini...

PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appointment of Dr. Karen C...

Aeva Technologies Inc. (AEVA) is expected to report $-0.59 for Q1 2025 Brasilagro Brazilian Agric Real Estate Co Sponsored ADR (Brazil) (LND) is expected to report for Q3 2025 Omron Corporation ADR (OMRNY) is expected to report for Q4 2025 Sezzle Inc. (SEZL) is expected to report $0.3...

2025-05-07 17:50:56 ET More on Context Therapeutics Seeking Alpha’s Quant Rating on Context Therapeutics Historical earnings data for Context Therapeutics Financial information for Context Therapeutics Read the full article on Seeking Alpha For...

CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, May 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (&#x...